59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial
N. Girard(Université de Versailles Saint-Quentin-en-Yvelines), M-J. Ahn(Samsung Medical Center), Min Hee Hong(Yonsei University), Paul Howarth(Daiichi Sankyo (United States)), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Michael Chargualaf(Daiichi Sankyo (United States)), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), M. Pérol(Centre Léon Bérard), Y. Le Guen(Hôpital Pontchaillou), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Jacob Sands(Harvard University), Deise Uema(Daiichi Sankyo (United States)), Isamu Okamoto(Kyushu University Hospital), Aaron Lisberg(APLA Health), Shunichi Sugawara(Sendai Kousei Hospital), Y. Zhang(Daiichi Sankyo (United States)), Enriqueta Felip(Institut Català d'Ornitologia), David Vicente Baz(Hospital Universitario Virgen Macarena), Ria Cornelissen(Erasmus MC Cancer Institute), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k